CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy

Immunotherapy is a promising therapeutic area in cancer and chronic viral infections. An important component of immunotherapy in these contexts is the activation of innate immunity. Here we investigate the potential for CD169 (Siglec 1) expression on monocytes to serve as a robust biomarker for acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lende, Stine Sofie Frank, Pahus, Marie Høst, Monrad, Ida, Olesen, Rikke, Mahr, Anna R., Vibholm, Line K., Østergaard, Lars, Søgaard, Ole Schmeltz, Andersen, Anna Halling Folkmar, Denton, Paul W., Tolstrup, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294151/
https://www.ncbi.nlm.nih.gov/pubmed/35865810
http://dx.doi.org/10.3389/fcimb.2022.919097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294151/
https://www.ncbi.nlm.nih.gov/pubmed/35865810
http://dx.doi.org/10.3389/fcimb.2022.919097

Ejemplares similares